Literature DB >> 17900820

l-[METHYL-(11)C] methionine positron emission tomography for target delineation in malignant gliomas: impact on results of carbon ion radiotherapy.

Pawinee Mahasittiwat1, Jun-Etsu Mizoe, Azusa Hasegawa, Hiroyuki Ishikawa, Kyosan Yoshikawa, Hideyuki Mizuno, Takeshi Yanagi, Ryou Takagi, Pittayapoom Pattaranutaporn, Hirohiko Tsujii.   

Abstract

PURPOSE: To assess the importance of (11)C-methionine (MET)-positron emission tomography (PET) for clinical target volume (CTV) delineation. METHODS AND MATERIALS: This retrospective study analyzed 16 patients with malignant glioma (4 patients, anaplastic astrocytoma; 12 patients, glioblastoma multiforme) treated with surgery and carbon ion radiotherapy from April 2002 to Nov 2005. The MET-PET target volume was compared with gross tumor volume and CTV, defined by using computed tomography/magnetic resonance imaging (MRI). Correlations with treatment results were evaluated between positive and negative extended volumes (EVs) of the MET-PET target for CTV.
RESULTS: Mean volumes of the MET-PET targets, CTV1 (defined by means of high-intensity volume on T2-weighted MRI), and CTV2 (defined by means of contrast-enhancement volume on T1-weighted MRI) were 6.35, 264.7, and 117.7 cm(3), respectively. Mean EVs of MET-PET targets for CTV1 and CTV2 were 0.6 and 2.2 cm(3), respectively. The MET-PET target volumes were included in CTV1 and CTV2 in 13 (81.3%) and 11 patients (68.8%), respectively. Patients with a negative EV for CTV1 had significantly greater survival rate (p = 0.0069), regional control (p = 0.0047), and distant control time (p = 0.0267) than those with a positive EV. Distant control time also was better in patients with a negative EV for CTV2 than those with a positive EV (p = 0.0401).
CONCLUSIONS: For patients with malignant gliomas, MET-PET has a possibility to be a predictor of outcome in carbon ion radiotherapy. Direct use of MET-PET fused to planning computed tomography will be useful and yield favorable results for the therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17900820     DOI: 10.1016/j.ijrobp.2007.06.071

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  16 in total

Review 1.  Glioblastoma multiforme: emerging treatments and stratification markers beyond new drugs.

Authors:  C von Neubeck; A Seidlitz; H H Kitzler; B Beuthien-Baumann; M Krause
Journal:  Br J Radiol       Date:  2015-07-10       Impact factor: 3.039

Review 2.  Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas.

Authors:  Nathalie L Albert; Michael Weller; Bogdana Suchorska; Norbert Galldiks; Riccardo Soffietti; Michelle M Kim; Christian la Fougère; Whitney Pope; Ian Law; Javier Arbizu; Marc C Chamberlain; Michael Vogelbaum; Ben M Ellingson; Joerg C Tonn
Journal:  Neuro Oncol       Date:  2016-04-21       Impact factor: 12.300

Review 3.  Carbon ion radiotherapy in the treatment of gliomas: a review.

Authors:  Timothy D Malouff; Jennifer L Peterson; Anita Mahajan; Daniel M Trifiletti
Journal:  J Neurooncol       Date:  2019-09-30       Impact factor: 4.130

4.  FET PET reveals considerable spatial differences in tumour burden compared to conventional MRI in newly diagnosed glioblastoma.

Authors:  Philipp Lohmann; Pantelis Stavrinou; Katharina Lipke; Elena K Bauer; Garry Ceccon; Jan-Michael Werner; Bernd Neumaier; Gereon R Fink; Nadim J Shah; Karl-Josef Langen; Norbert Galldiks
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-10-16       Impact factor: 9.236

5.  Evaluation of 11C-Methionine PET and Anatomic MRI Associations in Diffuse Intrinsic Pontine Glioma.

Authors:  Christopher L Tinkle; Elizabeth C Duncan; Mikhail Doubrovin; Yuanyuan Han; Yimei Li; Hyun Kim; Alberto Broniscer; Scott E Snyder; Thomas E Merchant; Barry L Shulkin
Journal:  J Nucl Med       Date:  2018-08-02       Impact factor: 10.057

6.  Assessment of various strategies for 18F-FET PET-guided delineation of target volumes in high-grade glioma patients.

Authors:  Hansjörg Vees; Srinivasan Senthamizhchelvan; Raymond Miralbell; Damien C Weber; Osman Ratib; Habib Zaidi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-09-26       Impact factor: 9.236

7.  Volumetry of [(11)C]-methionine PET uptake and MRI contrast enhancement in patients with recurrent glioblastoma multiforme.

Authors:  Norbert Galldiks; Roland Ullrich; Michael Schroeter; Gereon R Fink; Andreas H Jacobs; Lutz W Kracht
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01       Impact factor: 9.236

8.  Atypical basal ganglia germinoma presenting as cerebral hemiatrophy: diagnosis and follow-up with 11C-methionine positron emission tomography.

Authors:  Jeehun Lee; Bo Lyun Lee; Keon Hee Yoo; Ki Woong Sung; Hong Hoe Koo; Su Jin Lee; Joon Young Choi; Kyung-Han Lee; Jung Il Lee; Hyung-Jin Shin; Ji Hye Kim; Yeon Lim Suh; Ke Hyang Lee; Munhyang Lee
Journal:  Childs Nerv Syst       Date:  2008-08-19       Impact factor: 1.475

9.  Differentiation of glioblastomas from metastatic brain tumors by tryptophan uptake and kinetic analysis: a positron emission tomographic study with magnetic resonance imaging comparison.

Authors:  David O Kamson; Sandeep Mittal; Amy Buth; Otto Muzik; William J Kupsky; Natasha L Robinette; Geoffrey R Barger; Csaba Juhász
Journal:  Mol Imaging       Date:  2013 Jul-Aug       Impact factor: 4.488

10.  Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET/RANO group.

Authors:  Norbert Galldiks; Maximilian Niyazi; Anca L Grosu; Martin Kocher; Karl-Josef Langen; Ian Law; Giuseppe Minniti; Michelle M Kim; Christina Tsien; Frederic Dhermain; Riccardo Soffietti; Minesh P Mehta; Michael Weller; Jörg-Christian Tonn
Journal:  Neuro Oncol       Date:  2021-06-01       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.